3rd Quarter - Report

CARDINAL POINT PARTNERS for TONIX PHARMACEUTICALS, INC.

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Disaster Planning/Emergencies DIS

Medical Countermeasures research, development and acquisition in the Pandemic All-Hazards Preparedness and Response Act (S. 2333).

LobbyistCovered position, as disclosed
STEVEN A WOLFE —

Contacted: Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 2333 (118th)

Budget/Appropriations BUD

Biodefense medical countermeasures research and development in the Defense Appropriations Act for FY 2025 (H.R. 8774, S. 4921) National Institutes of Health research on Long COVID in the Labor-HHS Appropriations Act for FY2025 National Institutes of Health research on cocaine abuse treatments in the Labor-HHS Appropriations Act for FY2025 (H.R. 9029, S. 4942)

LobbyistCovered position, as disclosed
STEVEN A WOLFE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 8774 (118th), S. 4942 (118th), H.R. 9029 (118th), S. 4921 (118th)

Defense DEF

Biodefense research in the National Defense Authorization Act for FY2025 (H.R. 8070 and S. 4638)

LobbyistCovered position, as disclosed
STEVEN A WOLFE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 4638 (118th), H.R. 8070 (118th)

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.